Antisense Oligomer-Based Therapeutic Platform for Inhibiting Coronavirus Replication and Treating Viral Infections

Background

Coronaviruses, including SARS-CoV-2, SARS-CoV, and related β-coronaviruses, are responsible for significant global health challenges, as demonstrated by the COVID-19 pandemic. These viruses primarily infect respiratory epithelial cells but can also target a wide range of tissues, leading to severe and sometimes fatal disease. The rapid transmission, high mutation rates, and emergence of new variants have underscored the urgent need for effective antiviral therapies that can be rapidly deployed and are broadly active against multiple coronavirus strains. Traditional approaches, such as vaccines and small-molecule drugs, have limitations in terms of speed of development, adaptability to emerging variants, and efficacy in immunocompromised populations, highlighting the necessity for innovative antiviral strategies that directly target viral replication mechanisms.

Current antiviral treatments for coronaviruses face several significant challenges. Small-molecule inhibitors often target viral enzymes, such as proteases or polymerases, but these can quickly become ineffective due to viral mutations that confer drug resistance. Monoclonal antibodies, while effective in neutralizing specific viral strains, may lose efficacy as new variants emerge with mutations in the spike protein. Additionally, many nucleic acid-based therapeutics suffer from poor stability in biological environments and inefficient delivery into target cells, limiting their practical application. The lack of broad-spectrum antivirals that can inhibit a wide range of coronaviruses, combined with delivery and stability issues, has hindered the development of universally effective treatments for both current and future coronavirus outbreaks.

Technology

This technology utilizes phosphorodiamidate morpholino oligomers (PMOs), which are synthetic nucleic acid analogs engineered to resist degradation by cellular nucleases. Each PMO is designed with an antisense sequence, typically 25 nucleotides in length, that specifically binds to a highly conserved 5’ region of the coronavirus genome, particularly the translation initiation complex overlapping the ppl a gene start site and the 5’ untranslated region (UTR). By binding to this region, the PMO effectively blocks ribosome attachment, thereby inhibiting viral protein synthesis and replication. To ensure efficient delivery into target cells, the PMOs are conjugated to positively charged delivery moieties such as octaguanidine dendrimers, which facilitate cellular uptake through enhanced membrane translocation. The antiviral agents are formulated with pharmaceutically acceptable carriers, allowing for a wide range of administration routes, including intravenous, intranasal, oral, and topical, and are suitable for both treatment and prevention of coronavirus infections.

What differentiates this technology is its strategic targeting of a highly conserved and functionally essential region of the coronavirus genome, which is shared across multiple β-coronaviruses, including SARS-CoV-2. This broad-spectrum approach increases the likelihood of efficacy against current and emerging coronavirus strains. The use of PMOs provides high specificity and stability, while resistance to nucleases ensures prolonged activity within the body. The incorporation of octaguanidine dendrimers as delivery vehicles further enhances intracellular uptake, overcoming a common barrier faced by nucleic acid-based therapeutics. Additionally, the platform’s versatility in formulation and administration, combined with demonstrated low toxicity and potent inhibition of viral replication in both in vitro and in vivo studies, positions it as a robust and adaptable antiviral solution for a range of clinical and prophylactic applications.

Benefits

• Highly specific inhibition of coronavirus replication by targeting a conserved 5’ untranslated region and translation initiation site of the viral genome.
• Use of nuclease-resistant phosphorodiamidate morpholino oligomers (PMOs) ensures stability and durability inside cells.
• Enhanced intracellular delivery through conjugation with positively charged octaguanidine dendrimers, improving cellular uptake and antiviral efficacy.
• Broad-spectrum antiviral potential against multiple β-coronaviruses, including SARS-CoV-2, SARS-CoV, and related viruses.
• Versatile pharmaceutical formulations and multiple administration routes enable tailored treatment options for systemic or local delivery.
• Low toxicity profile with demonstrated safety in preclinical studies supports therapeutic use.
• Effective in vitro and in vivo reduction of viral RNA and protein levels, leading to potent suppression of viral replication.
• Potential application for treatment, prevention, and control of coronavirus infections in humans, animals, and donated tissues or organs.

Applications

• COVID-19 therapeutic drug development
• Broad-spectrum coronavirus prophylaxis
• Antiviral treatment for organ transplants
• In vitro coronavirus research reagents

Additional info

Phosphorodiamidate morpholino oligomers (PMOs), nuclease-resistant nucleic acid analogs, contain antisense sequences targeting conserved coronavirus 5’ genomic regions. Conjugated to cationic delivery moieties, these PMOs prevent ribosome attachment to viral mRNA, inhibiting protein translation and replication. These agents are formulated for therapeutic administration to treat or prevent coronavirus infections.